Answers are grounded in this paper and cite their sources.
Chronic myelomonocytic leukaemia (CMML) is a prototypic myeloid neoplasm that associates features of myelodysplastic syndromes and myeloproliferative neosplasms. This rare and severe overlap disease is a very diverse clinical entity. Yet, genomic underpinnings of CMML combine a restricted number of somatic mutations in DNA methylation, histone modifier, splicing factor and signaling genes [1]. The discordance between mutational simplicity and clinical heterogeneity has suggested multiple explanations, from underestimation of genetic diversity to a prominent role of epigenomic and cell extrinsic factors [2, 3].
No takes yet. Share an insight, caveat, or question.
Éric Solary (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: